HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human
HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human

Immobilized HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for HLA-A*02:01&B2M&PRAME TCR, hFc Tag with the EC50 of 55.4 ng/ml determined by ELISA.

HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human

The purity of HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human

HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human

PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited.
Z06592
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer[Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and SLLQHLIGL peptide]
Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&SLLQHLIGL		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 50.40 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 51-58 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human
    • HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human

    Immobilized HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for HLA-A*02:01&B2M&PRAME TCR, hFc Tag with the EC50 of 55.4 ng/ml determined by ELISA.

  • HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human
    • HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human

    The purity of HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human
    • HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human

    HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited.
Synonyms PRAME; OIP-4; OIP4; MAPE

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.